[Taipei, Feb 23] — TherapiAI, a leader in AI-driven pharmaceuticals, announced today the launch of the world’s first GMP AI Agent specifically engineered for Pharmaceutical CDMOs. The agent features advanced RAG (Retrieval-Augmented Generation) capabilities for global regulations, including FDA and ICH guidelines, enabling enterprises to navigate shifting regulatory landscapes in real-time.
Currently, TherapiAI has initiated strategic collaborations with overseas CDMOs. The upcoming Version 2.0, slated for mid-October, will introduce automated document verification. By leveraging intelligent cross-referencing and risk prediction, the platform helps CDMOs eliminate compliance uncertainty and drastically shorten document preparation cycles. This marks the dawn of “Smart Compliance” in the pharma industry—minimizing approval delays and accelerating the journey from lab to market.
The global biologics market continues its rapid expansion. According to Grand View Research, the market reached $400 billion in 2024 and is projected to exceed $650 billion by 2030, maintaining a CAGR of 8.5% from 2025 to 2030. However, regulatory compliance remains the industry’s most formidable challenge. Historically, pharmaceutical companies have faced stringent regulatory scrutiny, where even the slightest documentation error could derail an entire development timeline.
For pharmaceutical CDMOs, the greatest fear is that a single minor error could delay a client’s drug approval and market launch. Our GMP AI Agent acts as a high-speed compliance assistant, enabling CDMOs to complete rigorous checks before submission, ensuring documents are processed faster and with superior accuracy.” — Michael Han, Founder & CEO of TherapiAI
This GMP AI Agent directly tackles critical industry pain points. It instantly searches, cross-references, and interprets international regulatory texts—such as those from the FDA, EMA, and ICH—enabling R&D and Regulatory Affairs teams to rapidly identify the accurate regulatory basis for their work.
Simultaneously, leveraging a built-in risk prediction model, it simulates potential inquiries from reviewers and flags high-risk sections via a “risk map,” effectively subjecting documents to a “pre-review” prior to submission. Furthermore, the system continuously monitors the latest guidelines and Q&As from the FDA, EMA, and ICH, ensuring the team remains aligned with the most current standards.
More importantly, TherapiAI positions the GMP AI Agent as an ‘End-to-End Compliance Partner,’ playing a critical role across every stage from R&D to regulatory submission. It automatically detects inconsistencies or omissions across cross-departmental documents and ensures total alignment through advanced version control—preventing costly delays caused by versioning errors.
The system also consolidates submission experiences, auditor feedback, and common deficiencies into an ‘internal knowledge base’ for training new staff and shortening the onboarding period. Furthermore, it can integrate experimental data to automatically generate initial drafts of regulatory documents according to client needs, accelerating the efficiency of cross-referencing and responses to help pharmaceutical companies avoid regulatory holds and supplemental filing delays.
Ultimately, these benefits translate into tangible results: shortened time-to-market, reduced reliance on external consultants, and enabling QA (Quality Assurance) and RA (Regulatory Affairs) personnel to focus on high-value strategic decision-making.
Looking ahead, TherapiAI will continue to evolve the GMP AI Agent by introducing ‘Rapid Cross-Referencing’ and real-time regulatory update alerts, enabling teams to instantly cite relevant clauses and make necessary adjustments. All retrieval logs and feedback will continuously accumulate as proprietary knowledge assets, helping CDMOs gain a competitive edge in time and success rates within the global pharmaceutical race.
